ITCI Intra-Cellular Therapies: Rasio rega marang prakiraan pendapatan
The forward P/S ratio illustrates the valuation dynamics of Intra-Cellular Therapies (ITCI). Growth is driven by the success of CAPLYTA, a unique schizophrenia treatment devoid of tremor-related side effects. The 20.60 metric confirms current levels as the company expands the drug's application for depression. Robust cash flow and strong market momentum ensure sustainable margins and a confident growth trajectory.
intracellulartherapies.com (ITCI) - rincian metrik lan laporan keuangan
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Intra-Cellular Therapies|ITCI - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Intra-Cellular Therapies, Inc.|ITCI - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Intra-Cellular Therapies, Inc.|ITCI - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Intra-Cellular Therapies|Indikator likuiditas cepet intracellulartherapies.com
- data bathi bisnis lan rasio investasi:
ITCI - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Intra-Cellular Therapies|ITCI - Nilai perusahaan marang bathi resik|Pangali Forward P/E Intra-Cellular Therapies, Inc.|ITCI - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Intra-Cellular Therapies, Inc.|ITCI - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Intra-Cellular Therapies|ITCI - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan intracellulartherapies.com|ITCI - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Intra-Cellular Therapies
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis fundamental perusahaan:ITCI (Intra-Cellular)
The efficiency of Caplyta commercialization through clinic partnerships directly impacts the projected market cap-to-revenue ratio for Intra-Cellular Therapies (ITCI). This indicator compares the current market value of Intra-Cellular Therapies (ITCI) with projected 10-K/10-Q financial data, allowing investors to perform a real-time assessment of valuation fairness relative to expected sales and promptly identify risks of overpayment or business undervaluation.
Pesaing wigati
Multiplikator Forward P/S BIIB (Biogen)|Neurocrine (NBIX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RGC - Rasio rega marang prakiraan pendapatan|AXSM: Rasio rega marang prakiraan pendapatan|ACADIA Pharmaceuticals (ACAD) - Rasio rega marang prakiraan pendapatan|XENE (xenon-pharma.com) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan VKTX|Multiplikator Forward P/S Supernus Pharmaceuticals, Inc.|Rasio rega marang prakiraan pendapatan Catalyst Pharmaceuticals Inc (CPRX)|Rasio rega marang prakiraan pendapatan DNLI (Denali Corp)|Multiplikator Forward P/S HRMY (Harmony Biosciences)|Multiplikator Forward P/S biohavenpharma.com BHVN|AMLX - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan TRVI (Trevi Therapeutics Inc)|PRAX (Praxis Medicines) - Multiplikator forward rega marang pendapatan|Anavex Life Sciences Corp - Rega forward marang dodolan|Multiplikator forward rega marang pendapatan CBLL|PRTA (Prothena Corporation) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S ALEC|ANNX (Annexon Biosciences) - Rega forward marang dodolan|Multiplikator Forward P/S OMER (Omeros)|Neurogene Therapeutics (NGNE) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ACIU - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan VYGR (voyagertherapeutics.com)|NMRA: Multiplikator Forward P/S|Scilex Holding (SCLX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Tevogen Bio Holdings, Inc.|Alpha Cognition Corp - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CGTX|Rasio kapitalisasi marang dodolan sing dikarepake inhibikase.com|Multiplikator Forward P/S SAVA (Cassava Sciences)|Assertio Holdings (ASRT) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|COYA - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Vistagen Therapeutics VTGN|OVID: Multiplikator Forward P/S|ABOS - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan CRVO|ATHE (Alterity Therapeutics Ltd) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S CLNN|Multiplikator forward rega marang pendapatan pepgen.com PEPG|Multiplikator Forward P/S JUNS (Jupiter Neurosciences Inc)|Rasio kapitalisasi marang dodolan sing dikarepake relmada.com (RLMD)|ANVS - Rasio rega marang prakiraan pendapatan|GRCE (Grace Therapeutics, Inc.) - Kapitalisasi marang prakiraan pendapatan|AIFF: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Klotho Neurosciences (KLTO)|Multiplikator forward rega marang pendapatan NRSN|Multiplikator Forward P/S revivapharma.com|Rasio rega marang prakiraan pendapatan MetaVia Inc (MTVA)|NRXS (NeurAxis Inc.) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Helius Medical Technologies HSDT|Passage Bio Inc. (PASG) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Neuphoria - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake minervaneurosciences.com NERV|Athira Pharma (ATHA) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan ADXN|Multiplikator forward rega marang pendapatan ALZN|CYCN (Cyclerion) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Protagenic Therapeutics (PTIX)|KTTA (pasitheaclinics.com) - Rega forward marang dodolan|Multiplikator Forward P/S CRGT (Cortigent)|Multiplikator Forward P/S Avenue Therapeutics Inc. ATXI|BCLI: Multiplikator forward rega marang pendapatan|Prakiraan rega marang pendapatan Cara Therapeutics Inc (CARA)|CHRO: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Eliem Therapeutics Inc.|LBPH (Longboard Pharmaceuticals, Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Marinus Pharmaceuticals Inc MRNS|Rasio rega marang prakiraan pendapatan NKGen (NKGN)|Rasio rega marang prakiraan pendapatan NRBO (NeuroBo Pharma)|Rasio rega marang prakiraan pendapatan Sage Therapeutics, Inc. SAGE|synaptogen.com - Rasio rega marang prakiraan pendapatan|TRVN: Multiplikator forward rega marang pendapatan|VIGL - Multiplikator Forward P/S|Anew Medical (WENA) - Rasio rega marang prakiraan pendapatan|CERE (Cerevel Corp) - Rasio rega marang prakiraan pendapatan
